Targeted Inhibition Of The FACT (Facilitates Chromatin Transcription) Complex As A Novel Therapeutic Approach In Aggressive Childhood Cancers
Funder
National Health and Medical Research Council
Funding Amount
$1,029,488.00
Summary
Our research focusses on the most aggressive of all childhood cancers, and our aim is to develop novel therapies for these malignancies. We have discovered a new drug target called "FACT" in aggressive brain and solid tumours of childhood. Targeting FACT with a new class of drugs termed "curaxins" has a powerful anti-tumour effect. We aim to investigate the potential of these drugs as a new, effective therapy for incurable childhood cancers.
TARGETING A NOVEL DNA-DAMAGE SIGNALING PATHWAY TO TREAT GLIOMAS
Funder
National Health and Medical Research Council
Funding Amount
$97,783.00
Summary
Glioblastoma Multiforme (GBM) is a high grade brain tumour for which current treatment modalities are inadequate. Tumour recurrence is almost inevitable and average life expectancy is measured in months. We have identified two proteins as potential therapeutic targets and demonstrated that depleting these proteins in vitro severely impacts on tumour cell viability. We will investigate the impact of targeting these proteins in mouse models of human gliomas and dissect the mechanism that leads to ....Glioblastoma Multiforme (GBM) is a high grade brain tumour for which current treatment modalities are inadequate. Tumour recurrence is almost inevitable and average life expectancy is measured in months. We have identified two proteins as potential therapeutic targets and demonstrated that depleting these proteins in vitro severely impacts on tumour cell viability. We will investigate the impact of targeting these proteins in mouse models of human gliomas and dissect the mechanism that leads to their upregulation in tumour cells.Read moreRead less
EphA2 And EphA3 Maintain Tumour Initiating Cells And Are Therapeutic Targets In Brain Cancer
Funder
National Health and Medical Research Council
Funding Amount
$612,860.00
Summary
High-grade glioma (HGG) is the most common adult brain cancer; current treatments have increased survival times by months only. Our studies have shown brain cancer specific expression of a family of cell surface proteins called Eph receptors. Furthermore we have shown targeting these receptors with Eph antibodies leads to a significant reduction in brain cancer tumour growth. We now propose to test targeting these receptors in combination to achieve greater responses with minimal side effects.
X-RATE: A Novel Radiation Detector Platform To Realize New Opportunities In Radiotherapy At The Australian Synchrotron
Funder
National Health and Medical Research Council
Funding Amount
$347,541.00
Summary
Microbeam Radiation Therapy (MRT) is an emerging X-ray radiosurgery modality that offers new hope for the treatment of brain cancer and other human brain diseases. A tissue equivalent radiation dosimetry system is essential for upcoming MRT human trials to precisely verify treatment plans. We are recognized world leaders in real-time silicon detector instrumentation for radiation dosimetry. We plan to develop and demonstrate X-RATE, the X-ray Real-time Active Tissue Equivalent dosimeter.
Radiosensitisation Of Diffuse Intrinsic Pontine Gliomas By Modulating Glucose Metabolism
Funder
National Health and Medical Research Council
Funding Amount
$325,000.00
Summary
Diffuse intrinsic pontine glioma (DIPG) represents the most aggressive cancer of childhood with no effective treatment available and radiotherapy is the only form of treatment that offers a transient benefit. We have successfully grown the first DIPG cells in the laboratory and found a new approach to radiosensitise them by targeting glucose metabolism. We will build on these findings and develop this treatment strategy to make this novel therapy available to children with this deadly disease.
Targeting Mitochondrial Metabolism In Diffuse Intrinsic Pontine Gliomas As A Novel Therapeutic Strategy
Funder
National Health and Medical Research Council
Funding Amount
$607,796.00
Summary
Diffuse Intrinsic Pontine Glioma (DIPG) represents the most aggressive cancer of childhood, with no effective treatments available, and almost all children dying within one year of diagnosis. We have successfully grown the first DIPG cells in the laboratory and found a new approach to attack them, by specifically targeting the cell's power source - the mitochondria. We will build on these findings and develop this treatment strategy with the aim to make this novel therapy available to children w ....Diffuse Intrinsic Pontine Glioma (DIPG) represents the most aggressive cancer of childhood, with no effective treatments available, and almost all children dying within one year of diagnosis. We have successfully grown the first DIPG cells in the laboratory and found a new approach to attack them, by specifically targeting the cell's power source - the mitochondria. We will build on these findings and develop this treatment strategy with the aim to make this novel therapy available to children with this deadly disease.Read moreRead less